Table 1: Clinical characteristics of patients according to ATG administration.
| Characteristic | ATG+; n = 11 | ATG -; n = 11 |
|---|---|---|
| Age (median, years) Gender (M/F ratio) |
49 (18-73) 8/3 |
49 (24-64) 6/5 |
| Diagnosis:
AML MDS sAA MPD CML CLL |
4 (36%) 0 3 (27%) 2 (18%) 1 (9%) 1 (9%) |
4 (36%) 3 (27%) - 2 (18%) 1 (9%) 1 (9%) |
| Disease status before alloSCT:
CR Non CR |
5 (45%) 6 (55%) |
5 (45%) 6 (55%) |
| Cytogenetic and molecular genetic at the time of diagnosis:a
Adverse risk Intermediate and favorable risk |
4 (36%) 7 (64%) |
4 (36%) 7 (64%) |
| Conditioning:
MAC b RIC c Non-Myeloablative d |
5 (45.5%) 5 (45.5%) 1 (9%) |
3 (27%) 8 (73%) - |
| Donor's age (median, range) | 45 (18-66) | 49 (21-65) |
| Donor's gender (M/F ratio) | 4/7 | 7/4 |
| CD34+ × 106/kg in transplant | 7.0 (3.2-13.6) | 5.8 (4.0-8.0) |
| Engraftment:
WBC > 1.0/ml (median day, range) Platelets > 50/ml (median day, range) |
16 (12-0) 16 (12-25) |
15 (11-18) 16 (10-20) |
n: Number of Patients; M: Male; F: Female; AML: Acute Myeloid Leukemia; MDS: Myelodysplastic Syndrome; sAA: Severe Aplastic Anemia; MPD: Myeloproliferative Disorders; CML: Chronic Myeloid Leukemia; CLL: Chronic Lymphatic Leukemia; CR: Complete Remission; MAC: Myeloablative Conditioning; RIC: Reduced Intensity Conditioning; non-Myelo: Non-Myeloablative conditioning; WBC: White Blood Cells. aThe cytogenetic risk groups were defined as follows: adverse risk, -5/5q-, -7/7q-, abn(3q) (excluding t(3;5), t(11q23) (excluding t(9;11) and t(11;19)), abn(17p), complex aberrations (≥ 4 independent aberrations); intermediate risk, patients without low risk or high risk constellations; favorable risk, t(15;17), inv(16)/t(16;16), and t(8;21) irrespective of additional cytogenetic abnormalities [36]. bMAC: 12 Gy Total Body Irradiation and Cyclophosphamide (N = 4), Busulfan and Cyclophosphamide (n = 6). cRIC: Treosulfan and Fludarabin and (n = 6), FLAMSA protocol (n = 3), and Fludarabin and Melphalan (n = 2). dnon-myeloablative conditioning: 2 Gy Of Total Body Irradiation.